Uncategorized

Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Nxera Pharma notes that its partner Neurocrine Biosciences Inc., a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants – see Neurocrine press announcement here.

Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults Read More »

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05%, a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in key regions of the Middle East and North Africa.

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

Tri-Tech expands emergency medical offering with the strategic acquisition of SAM Medical

Tri-Tech Forensics, Inc., a leading provider of tactical emergency medical solutions and human identification kits, is pleased to announce the acquisition of SAM® Medical, a globally renowned provider of innovative medical devices and trauma care solutions including tourniquets, hemostatics, splints, pelvic binders, and intraosseous access systems.

Tri-Tech expands emergency medical offering with the strategic acquisition of SAM Medical Read More »

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda announced financial results for fiscal year 2023, delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact.

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion Read More »

Head-to-head Superiority to High-dose Dulaglutide: Innovent’s First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints

Innovent Biologics, Inc. announces that the Phase 3 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese subjects with type 2 diabetes met the primary endpoint.

Head-to-head Superiority to High-dose Dulaglutide: Innovent’s First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints Read More »

Scroll to Top